Catalyst Health Ventures Wins Healthcare Fund of the Year at the New England Venture Capital Association's 2019 NEVY Awards

Friday, May 10, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

BOSTON, May 10, 2019 /PRNewswire/ -- Catalyst Health Ventures was announced as the winner for Healthcare Fund of the Year at 'The 007th Annual NEVY Awards', hosted by the New England Venture Capital Association and presented by Dell Technologies. In addition to winning healthcare fund of the year, Catalyst had two portfolio companies nominated for "Medtech

Company of the year" (Augmenix and Conformal Medical, Inc.) and Augmenix was declared winner.

The NEVYs, now in their seventh year, celebrate New England's top innovators across the life science, healthcare and technology communities in the region. As New England's premier awards program for the startup and venture ecosystems, and the only one to truly unite the technology, healthcare and life science communities, the NEVYs honor both early- and late-stage companies, as well as the venture capitalists who support them, and cover a wide spectrum of the region's thriving industry clusters. This year's 12 award categories recognize local companies and their investors, with final winners selected by the NEVYs Technology, Healthcare and Life Sciences Academies. Additionally, this was the first year in which Healthcare had a dedicated Academy distinct from Life Sciences, reflecting Boston's ascension as a healthcare innovation and investing hub.

The Healthcare Fund of the Year honor goes to companies exemplifying New England's leading place in the industry.  "Dell Technologies is proud to join the New England innovation and venture communities to recognize the outstanding achievements of companies in the region doing revolutionary things in technology, life science and healthcare," said Matt Baker, senior vice president of Dell EMC Strategy and Planning. "We are honored to stand next to like-minded companies who are fueled by a similar desire to create innovative technologies and solutions that drive human progress and will enable our world in the digital future."

"The NEVYs are always an event to remember, and this year was no different! We had a great turnout for this year's celebration and were proud to continue recognizing those in our region's first-class innovation economy," said NEVCA President Jody Rose. "New England has made a significant mark on the national startup and venture ecosystem, across tech, healthcare and life sciences, and will continue to do so. This is the place to be to originate and drive innovation. Congratulations to Catalyst Health Ventures on winning the Healthcare Fund of the Year and Medtech Company of the Year.

About the New England Venture Capital Association

The New England Venture Capital Association (NEVCA) invests in the entrepreneurial ecosystem on behalf of the VC community through program-building, policy work, marketing and events. From celebrations (the NEVY Awards) to content series (VC Briefings and Syndicate Sessions), workforce development programs (TechGen and Hack.Diversity) to advocacy and legislation (equity and inclusion initiatives and immigration reform), the NEVCA is at once a network, catalyst, and resource for the innovation economy.

About Catalyst Health Ventures

Catalyst Health Ventures (CHV) is a venture capital firm investing in disruptive solutions for global, unmet healthcare needs. CHV focuses on early-stage opportunities across medical devices, medical technology, diagnostics, digital health and life science tools. CHV portfolio companies provide strong clinical value propositions and cost savings across major markets including cancer, cardiovascular disease, metabolic disease, and women's health.

For more information on Catalyst Health Ventures please visit: To learn more about the New England Venture Capital Association, check out their website at

CONTACT: Darshana Zaveri,

Cision View original content:

SOURCE Catalyst Health Ventures

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store